Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth

Neoplasia

Volumn 7, Issue 6, 2005, Pages 545-555

  Corvinus, Florian M ^a   Orth, Carina ^a   Moriggl, Richard ^b   Tsareva, Svetlana A ^a   Wagner, Stefan ^a   Pfitzner, Edith B ^c   Baus, Daniela ^c   Kaufmann, Roland ^a   Huber, Lukas A ^d   Zatloukal, Kurt ^e   Beug, Hartmut ^b   Öhlschläger, Peter ^a   Schütz, Alexander ^f   Halbhuber, Karl Jürgen ^a   Friedrich, Karlheinz ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^c INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^d UNIVERSITY OF INNSBRUCK   (Austria)

^e UNIVERSITY OF GRAZ   (Austria)

^f UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cell proliferation; Colorectal cancer; JAK STAT pathway; STAT3; Xenograft

Indexed keywords

INTERLEUKIN 6; STAT3 PROTEIN; WNT1 PROTEIN;

ARTICLE; CANCER CELL; CANCER MORTALITY; CELL DIVISION; CELL PROLIFERATION; COLON MUCOSA; COLORECTAL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; XENOGRAFT;

EID: 22044437986     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04571     Document Type: Article

References (52)

1. Declan Fleming RY (1998). Colorectal cancer screening and follow-up. Surg Oncol 7, 125-137.
2. Oving IM and Clevers HC (2002). Molecular causes of colon cancer. Eur J Clin Invest 32, 448-457.
3. Grady WM and Markowitz SD (2002). Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 3, 101-128.
4. Ma AH, Xia L, Littman SJ, Swinler S, Lader G, Polinkovsky A, Olechnowicz J, Kasturi L, Lutterbaugh J, Modrich P, et al. (2000). Somatic mutation of hPMS2 as a possible cause of sporadic human colon cancer with microsatellite instability. Oncogene 19, 2249-2256.
5. Duval A and Hamelin R (2002). Genetic instability in human mismatch repair deficient cancers. Ann Genet 45, 71-75.
6. Boldrini L, Faviana P, Gisfredi S, Zucconi Y, Di Quirico D, Donati V, Berti P, Spisni R, Galleri D, Materazzi G, et al. (2002). Evaluation of telomerase in the development and progression of colon cancer. Int J Mol Med 10, 589-592.
7. Kielman MF, Rindapaa M, Gaspar C, van Poppel N, Breukel C, van Leeuwen S, Taketo MM, Roberts S, Smits R, and Fodde R (2002). APC modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling. Nat Genet 32, 594-605.
8. O'Shea JJ, Gadina M, and Schreiber RD (2002). Cytokine signaling in 2002: new surprises in the JAK/STAT pathway. Cell 109 (Supplement), S121-131.
9. Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, and Kishimoto T (1994). Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77, 63-71.
10. Levy DE and Lee CK (2002). What does Stat3 do? J Clin Invest 109, 1143-1148.
11. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, and Akira S (1997). Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 94, 3801-3804.
12. Bowman T, Garcia R, Turkson J, and Jove R (2000). STATs in oncogenesis. Oncogene 19, 2474-2488.
13. Bromberg J (2002). Stat proteins and oncogenesis. J Clin Invest 109, 1139-1142.
14. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, et al. (2001). Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20, 2499-2513.
15. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, and Darnell JE Jr (1999). Stat3 as an oncogene. Cell 98, 295-303.
16. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, et al. (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107, 351-362.
17. Epling-Burnette PK, Zhong B, Bai F, Jiang K, Bailey RD, Garcia R, Jove R, Djeu JY, Loughran TP Jr, and Wei S (2001). Cooperative regulation of Mcl-1 by Janus kinase/Stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J Immunol 166, 7486-7495.
18. Shen Y, Devgan G, Darnell JE Jr, and Bromberg JF (2001). Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc Natl Acad Sci USA 98, 1543-1548.
19. Ravandi F, Talpaz M, Kantarjian H, and Estrov Z (2002). Cellular signalling pathways: new targets in leukaemia therapy. Br J Haematol 116, 57-77.
20. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S, and Weinstein IB (2002). Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62, 3351-3355.
21. Niu G, Bowman T, Huang M, Shivers S, Reinigen D, Daud A, Chang A, Kraker A, Jove R, and Yu H (2002). Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21, 7001-7010.
22. Schaefer LK, Ren Z, Fuller GN, and Schaefer TS (2002). Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 21, 2058-2065.
23. Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, and Gao AC (2002). Stat3 activation in prostatic carcinomas. Prostate 51, 241-246.
24. Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, Baumann H, and Wetzler M (2002). Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 99, 252-257.
25. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, and Murai M (2002). Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 168, 762-765.
26. Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmüller U, Nakajima K, Hirano T, Horn F, and Behrmann I (1999). Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene 18, 3742-3753.
27. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, and Haque SJ (2002). Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21, 8404-8413.
28. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, and Fernandez-Luna JL (2002). Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21, 7611-7618.
29. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R, and Yu H (1999). Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59, 5059-5063.
30. Leong PL, Xi S, Drenning SD, Dyer KF, Wentzel AL, Lerner EC, Smithgall TE, and Grandis JR (2002). Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene 25, 2846-2853.
31. Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H, and Nevalainen MT (2003). Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 278, 27287-27292.
32. Kirito K, Nagashima T, Ozawa K, and Komatsu N (2002). Constitutive activation of Stat1 and Stat3 in primary erythroleukemia cells. Int J Hematol 75, 51-54.
33. Widschwendter A, Tonko-Geymayer S, Weite T, Daxenbichler G, Marth C, and Doppler W (2002). Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res 8, 3065-3074.
34. Vecsey-Semjen B, Becker KF, Sinski A, Blennow E, Vietor I, Zatloukal K, Beug H, Wagner E, and Huber LA (2002). Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers. Oncogene 21, 4646-4662.
35. Ory DS, Neugeboren BA, and Mulligan RC (1996). A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA 93, 11400-11406.
36. Kammer W, Lischke A, Moriggl R, Groner B, Ziemiecki A, Gurniak CB, Berg LJ, and Friedrich K (1996). Homodimerization of interleukin-4 receptor α chain can induce intracellular signaling. J Biol Chem 271, 23634-23637.
37. Lischke A, Moriggl R, Brändlein S, Berchtold S, Kammer W, Sebald W, Groner B, Liu X, Hennighausen L, and Friedrich K (1998). The interleukin-4 receptor activates STAT5 by a mechanism that relies upon the function of common γ chain. J Biol Chem 273, 31222-31229.
38. Halbhuber KJ and König K (2003). Modern laser scanning microscopy in biology, biotechnology and medicine. Ann Anat 185, 1-20.
39. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, and Tweardy DJ (1998). Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 102, 1385-1392.
40. Sano S, Itami S, Takeda K, Tarutani M, Yamaguohi Y, Miura H, Yoshikawa K, Akira S, and Takeda J (1999). Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 18, 4657-4668.
41. Burke WM, Jin X, Lin HJ, Huang M, Liu R, Reynolds RK, and Lin J (2001). Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 20, 7925-7934.
42. Li L and Shaw PE (2002). Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines. J Biol Chem 277, 17397-17405.
43. Schuringa JJ, Wierenga AT, Kruijer W, and Vellenga E (2000). Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 95, 3765-3770.
44. Angelo L, Talpaz M, and Kurzrook R (2002). Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res 62, 932-940.
45. Giri D, Ozen M, and Ittmann M (2001). Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159, 2159-2165.
46. Morin PJ (1999). Beta-catenin signaling and cancer. Bioessays 21, 1021-1030.
47. Morris AL, Clissold PM, Askham JM, Morrison EE, Moncur P, McCall SH, Coletta PL, Meredith DM, and Markham AF (2000). Truncated adenomatous polyposis coli (APC) tumour suppressor protein can undergo tyrosine phosphorylation. Eur J Cancer 36, 525-532.
48. Yamashita S, Miyagi C, Carmany-Rampey A, Shimizu T, Fuji R, Schier AF, and Hirano T (2002). Stat3 controls movements during zebrafish gastrulation. Dev Cell 2, 363-375.
49. Kolligs FT, Bommer G, and Goke B (2002). Wnt/beta-catenin/Tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion 66, 131-144.
50. Hsi LC, Angerman-Stewart J, and Eling TE (1999). Introduction of full-length APC modulates cyclooxygenase-2 expression in HT-29 human colorectal carcinoma cells at the translational level. Carcinogenesis 20, 2045-2049.
51. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, et al. (2002). Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62, 6659-6666.
52. Smith PC and Keller ET (2001). Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 48, 47-53.